...ProBioGen granted Novartis a non-exclusive license to use ProBioGen’s GlymaxX technology to enhance antibody-dependent cell-mediated cytotoxicity...
...reduce dosing requirements. ProBioGen said financial terms are not disclosed. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland ProBioGen AG...

...cytotoxicity (ADCC) activity on an undisclosed bispecific antibody in preclinical development to treat solid tumors. ProBioGen's...
...dosing requirements. The companies declined to disclose financial details. Merus B.V. , Utrecht, the Netherlands ProBioGen AG...

...Inhibrx received a non-exclusive license to use ProBioGen's GlymaxX technology to enhance antibody-dependent cellular cytotoxicity (ADCC...
...GlymaxX technology to enhance antibody-dependent cellular cytotoxicity (ADCC) activity for several undisclosed oncology antibodies. Additionally, ProBioGen...
...development and manufacturing services to help Inhibrx with process development for undisclosed recombinant therapeutic proteins. ProBioGen...

...Boehringer received a non-exclusive license to use ProBioGen's GlymaxX technology to enhance antibody-dependent cellular cytotoxicity (ADCC...
...jointly market the technology and offer it to customers royalty-free. Financial details were not disclosed. ProBioGen AG...

...Minapharm acquired 95% of ProBioGen for €30.4 million ($36.8 million), including undisclosed earn-outs. ProBioGen is a...
...and coagulation disorders (see BioCentury, April 23, 2007). Wieland Wolf was hired as CEO of ProBioGen...
...Wafik Bardissi replaces Hubertus Leonhardt as chairman of ProBioGen. Minapharm Pharmaceuticals S.A.E. (Cairo:MIPH), Cairo, Egypt ProBioGen AG...

...Affiris will use ProBioGen's Human Artificial Lymph Node (HuALN) technology to assist in the selection of...
...structures to predict drug-related effects. Further details were not disclosed. Affiris AG , Vienna, Austria ProBioGen AG...

...and the SHS management team. SHS investments include antibody company Affimed and recombinant protein company ProBioGen...

...principal at Apax Partners; Hing Kin Chan as CBO, formerly VP of commercial development at ProBioGen AG...